

DAFTAR PUSTAKA

- Abbas AK, 2018. Innate Immunity. In: Abbas AK, Lichtman AH & Pillai S, Eds. Cellular and Molecular Immunology, Ninth Edition. California: Elsevier Saunders 4: 57-86.
- Akira, S., Uematsu, S. and Takeuchi, O., 2006. Pathogen recognition and innate immunity. *Cell*, 124(4), pp.783-801.
- Akmal, M., Zely I., 2010. *Ensiklopedi Kesehatan Umum*. Yogyakarta: Ar-Ruzz Media.
- Al-Khafaji, A.H., Sharma, S. and Eschun, G., 2019. Multiple organ dysfunction syndrome in sepsis. *Drugs & Diseases> Infectious Diseases. Updated: Feb 5*.
- Almirall, J., Bolibar, I., Vidal, J., Sauca, G., Coll, P., Niklasson, B., Bartolome, M. and Balanzo, X., 2000. Epidemiology of community-acquired pneumonia in adults: a population-based study. *European Respiratory Journal*, 15(4), pp.757-763.
- Angele, M.K., Pratschke, S., Hubbard, W.J. and Chaudry, I.H., 2014. Gender differences in sepsis: cardiovascular and immunological aspects. *Virulence*, 5(1), pp.12-19.
- Angus, D.C. and Van der Poll, T., 2013. Severe sepsis and septic shock. *New England Journal of Medicine*, 369(9), pp.840-851.
- Baharoon, S., Telmesani, A., Tamim, H., Alsafi, E., Aljohani, S., Mahmoud, E. and Al-Jahdali, H., 2015. Community-versus nosocomial-acquired severe sepsis and septic shock in patients admitted to a tertiary intensive care in Saudi Arabia, etiology and outcome. *Journal of infection and public health*, 8(5), pp.418-424.
- Becker, K., Heilmann, C. and Peters, G., 2014. Coagulase-negative staphylococci. *Clinical microbiology reviews*, 27(4), pp.870-926.
- Bertsias, G., Cervera, R. and Boumpas, D.T., 2012. Systemic lupus erythematosus: pathogenesis and clinical features. *EULAR textbook on rheumatic diseases, Geneva, Switzerland: European League Against Rheumatism*, pp.476-505.
- Blasius, A.L. dan Beutler, B., 2010. Intracellular toll-like receptors. *Immunity*, 32(3), pp.305-315.
- Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A., Schein, R.M. and Sibbald, W.J., 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest*, 101(6), pp.1644-1655.
- Botos, I., Segal, D.M. dan Davies, D.R., 2011. The structural biology of Toll-like receptors. *Structure*, 19(4), pp.447-459.
- Brandt, M., 2018. Introduction to Lipid Metabolism. [online] Rose-hulman.edu. Available at: https://www.rose-hulman.edu/~brandt/Chem330/Lipid_metab.pdf [Accessed 7 Aug. 2018].
- Carbone, F., Nencioni, A., Mach, F., Vuilleumier, N. and Montecucco, F., 2013. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. *Thrombosis and haemostasis*, 110(05), pp.854-868.
- Caroff, M., Karibian, D., Cavaillon, J.M. and Haeffner-Cavaillon, N., 2002. Structural and functional analyses of bacterial lipopolysaccharides. *Microbes and infection*, 4(9), pp.915-926.
- Ceccato, A. and Torres, A., 2018. Sepsis and community-acquired pneumonia. *Annals of Research Hospitals*, 2(7).

- Centers for Disease Control and Prevention, 2018. *Data and Reports*. [online] Available at: <https://www.cdc.gov/sepsis/datareports/index.html> [Accessed 7 Aug. 2018].
- Catapano, A.L., Pirillo, A., Bonacina, F. and Norata, G.D., 2014. HDL in innate and adaptive immunity. *Cardiovascular research*, 103(3), pp.372-383.
- Chapman, M.J., 2004. Are the effects of statins on HDL-cholesterol clinically relevant. *European Heart Journal Supplements*, 6(suppl_C), pp.C58-C63.
- Chong, D.L. and Sriskandan, S., 2011. Pro-inflammatory mechanisms in sepsis. In *Sepsis-Pro-Inflammatory and Anti-Inflammatory Responses* (Vol. 17, pp. 86-107). Karger Publishers.
- Cirstea, M., Walley, K.R., Russell, J.A., Brunham, L.R., Genga, K.R. and Boyd, J.H., 2017. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. *Journal of critical care*, 38, pp.289-294.
- Dahlan MS. (2013). Langkah – langkah membuat proposal penelitian bidang kedokteran dan kesehatan. Seri Evidence Based Medicine, edisi ke-2, Jakarta. Salemba Medika: 158 – 159.
- De La Rica, A.S., Gilsanz, F. and Maseda, E., 2016. Epidemiologic trends of sepsis in western countries. *Annals of translational medicine*, 4(17).
- Dembic, Z., 2015. Cytokines of the immune system: interleukins. The cytokines of the immune system the role of cytokines in disease related to immune response. San Diego: Mica Haley, pp.143-175.
- Feingold, K.R. and Grunfeld, C., 2011. The role of HDL in innate immunity. *Journal of lipid research*, 52(1), pp.1-3
- Gautier, T. and Lagrost, L., 2011. Plasma PLTP (phospholipid-transfer protein): an emerging role in ‘reverse lipopolysaccharide transport’ and innate immunity.
- Grunfeld, C., Marshall, M., Shigenaga, J.K., Moser, A.H., Tobias, P. and Feingold, K.R., 1999. Lipoproteins inhibit macrophage activation by lipoteichoic acid. *Journal of lipid research*, 40(2), pp.245-252.
- Grunfeld, C. and Feingold, K.R., 2008. HDL and innate immunity: a tale of two apolipoproteins. *Journal of lipid research*, 49(8), pp.1605-1606.
- Hall, M.J., Williams, S.N., DeFrances, C.J. and Golosinskiy, A., 2011. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals.
- Hannuksela, M., Marcel, Y.L., Kesäniemi, Y.A. and Savolainen, M.J., 1992. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. *Journal of lipid research*, 33(5), pp.737-744.
- Heb, N., Waldow, F., Kohler, T.P., Rohde, M., Kreikemeyer, B., Gómez-Mejia, A., Hain, T., Schwudke, D., Vollmer, W., Hammerschmidt, S. and Gisich, N., 2017. Lipoteichoic acid deficiency permits normal growth but impairs virulence of *Streptococcus pneumoniae*. *Nature communications*, 8(1), p.2093.
- Heidelbaugh, J.J. and Bruderly, M., 2006. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. *American family physician*, 74(5).

- Henriksen, D.P., Pottegård, A., Laursen, C.B., Jensen, T.G., Hallas, J. and Lassen, A.T., 2015. Risk factors for hospitalization due to community-acquired sepsis—a population-based case-control study. *PLoS One*, *10*(4), p.e0124838.
- Hewing, B., Moore, K.J. and Fisher, E.A., 2012. HDL and cardiovascular risk: time to call the plumber. *Circulation Research*, *111*(9), pp.1117-1120.
- Irawan, D., Hamidah, P., Triyono, E.A., Bramantono, A.V., Hadi, U., Nasronudin, S. and Soewandojo, E., 2012. Profil penderita sepsis akibat bakteri penghasil ESBL. *J Peny Dalam*, *13*(1), p.63.
- Jiao, Y.L. and Wu, M.P., 2008. Apolipoprotein AI diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. *Cytokine*, *43*(1), pp.83-87.
- Kaji, H., 2013. High-density lipoproteins and the immune system. *Journal of lipids*, 2013.
- Kardassis, D., Mosialou, I., Kanaki, M., Tiniakou, I. and Thymiakou, E., 2014. Metabolism of HDL and its regulation. *Current medicinal chemistry*, *21*(25), pp.2864-2880.
- Kawai, T. dan Akira, S., 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. *Immunity*, *34*(5), pp.637-650.
- Keene, D., Price, C., Shun-Shin, M.J. and Francis, D.P., 2014. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. *Bmj*, *349*, p.g4379.
- King, M., 2018. Lipoproteins, Lipoprotein Metabolism and Disease [LDL, HDL, Lp(a)]. [online] [Themedicalbiochemistrypage.org](https://themedicalbiochemistrypage.org). Available at: <https://themedicalbiochemistrypage.org/lipoproteins.php#hdl> [Accessed 19 Aug. 2018].
- Kitchens, R.L. and Thompson, P.A., 2003. Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: roles of soluble CD14, LBP, and acute phase lipoproteins. *Journal of endotoxin research*, *9*(2), pp.113-118.
- Lamar, C.D., Hurley, R.A. and Taber, K.H., 2011. Sepsis-associated encephalopathy: review of the neuropsychiatric manifestations and cognitive outcome. *The Journal of neuropsychiatry and clinical neurosciences*, *23*(3), pp.237-241.
- Levy, M.M., Fink, M.P., Marshall, J.C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S.M., Vincent, J.L. and Ramsay, G., 2003. 2001 sccm/esicm/accp/ats/sis international sepsis definitions conference. *Intensive care medicine*, *29*(4), pp.530-538.
- Lewis, D.H., Chan, D.L., Pinheiro, D., Armitage-Chan, E. and Garden, O.A., 2012. The immunopathology of sepsis: pathogen recognition, systemic inflammation, the compensatory anti-inflammatory response, and regulatory T cells. *Journal of Veterinary Internal Medicine*, *26*(3), pp.457-482.
- Lie, K.C., Lau, C.Y., Chau, N.V.V., West, T.E. and Limmathurotsakul, D., 2018. Utility of SOFA score, management and outcomes of sepsis in Southeast Asia: a multinational multicenter prospective observational study. *Journal of intensive care*, *6*(1), p.9.
- Liljestrand, J.M., Paju, S., Buhlin, K., Persson, G.R., Sarna, S., Nieminen, M.S., Sinisalo, J., Mäntylä, P. and Pussinen, P.J., 2017. Lipopolysaccharide, a possible molecular mediator between periodontitis and coronary artery disease. *Journal of clinical periodontology*, *44*(8), pp.784-792.

- Maeda, K., Noguchi, Y. and Fukui, T., 2003. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. *Preventive medicine*, 37(4), pp.283-290.
- Malanovic, N. and Lohner, K., 2016. Gram-positive bacterial cell envelopes: The impact on the activity of antimicrobial peptides. *Biochimica et Biophysica Acta (BBA)-Biomembranes*, 1858(5), pp.936-946.
- Marshall, J.C., 2001. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. *Critical care medicine*, 29(7), pp S99-S106.
- Marti, B., Knobloch, M.I.C.H.A.E.L., Riesen, W.F. and Howald, H., 1991. Fifteen-year changes in exercise, aerobic power, abdominal fat, and serum lipids in runners and controls. *Medicine and science in sports and exercise*, 23(1), pp.115-122.
- Martin GS, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R, 2009. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. *Critical Care*. 13(3):1-14.
- Masana, L., Cabré, A., Heras, M., Amigó, N., Correig, X., Martínez-Hervás, S., Real, J.T., Ascaso, J.F., Quesada, H., Julve, J. and Palomer, X., 2015. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. *Atherosclerosis*, 238(2), pp.213-219.
- Massy, Z.A. and De Zeeuw, D., 2013. LDL cholesterol in CKD—to treat or not to treat. *Kidney international*, 84(3), pp.451-456.
- Mattsson, E., Van Dijk, H., Verhoef, J., Norrby, R. and Rollof, J., 1996. Supernatants from *Staphylococcus epidermidis* grown in the presence of different antibiotics induce differential release of tumor necrosis factor alpha from human monocytes. *Infection and immunity*, 64(10), pp.4351-4355.
- Mayr, F.B., Yende, S. and Angus, D.C., 2014. Epidemiology of severe sepsis. *Virulence*, 5(1), pp.4-11.
- McPherson, D., Griffiths, C., Williams, M., Baker, A., Klodawski, E., Jacobson, B. and Donaldson, L., 2013. Sepsis-associated mortality in England: an analysis of multiple cause of death data from 2001 to 2010. *BMJ open*, 3(8), p.e002586.
- Mizock, B.A., 2009. The multiple organ dysfunction syndrome. *Disease-a-Month*, 55(8), pp.476-526.
- Morgantini, C., Meriwether, D., Baldi, S., Venturi, E., Pinnola, S., Wagner, A.C., Fogelman, A.M., Ferrannini, E., Natali, A. and Reddy, S.T., 2014. HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. *Nutrition, Metabolism and Cardiovascular Diseases*, 24(6), pp.594-599.
- Morin, E.E., Guo, L., Schwendeman, A. and Li, X.A., 2015. HDL in sepsis—risk factor and therapeutic approach. *Frontiers in pharmacology*, 6, p.244.
- Morton, J., Ng, M.K., Chalmers, J., Woodward, M., Mancina, G., Poulter, N.R., Marre, M., Cooper, M.E., Zoungas, S. and ADVANCE collaborative group, 2013. The association of high-density lipoprotein cholesterol with cancer incidence in type ii diabetes: a case of reverse causality. *Cancer Epidemiology and Prevention Biomarkers*.
- Muennig, P., Sohler, N. and Mahato, B., 2007. Socioeconomic status as an independent predictor of physiological biomarkers of cardiovascular disease: evidence from NHANES. *Preventive medicine*, 45(1), pp.35-40.

- Munker R, 2007. Lymphocytosis, Lymphocytopenia, Lymphadenopathy, and Splenomegaly. In: Munker R, Hiller E, Glass J, Paquette R, Eds. *Modern Hematology: Biology and Clinical Management*, Second Edition. New Jersey: Humana Press. 217-224.
- Murch, O., Collin, M., Hinds, C.J. and Thiemermann, C., 2007. Lipoproteins in inflammation and sepsis. I. Basic science. *Intensive care medicine*, 33(1), pp.13-24.
- Murch, O., Collin, M., Hinds, C.J. and Thiemermann, C., 2007. Lipoproteins in inflammation and sepsis. I. Basic science. *Intensive care medicine*, 33(1), pp.13-24.
- Naresh, M., Vidyasagar, S. and Elagandula, J., 2015. Study of serum HDL levels in severe sepsis patients in medical intensive care unit. *International Journal of Scientific and Research Publication*, 5.
- Navab, M., Reddy, S.T., Van Lenten, B.J. and Fogelman, A.M., 2011. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. *Nature Reviews Cardiology*, 8(4), p.222.
- Neviere, R., 2013. Pathophysiology of sepsis. In *UpToDate*. UpToDate, Waltham (MA).
- Newton, K. and Dixit, V.M., 2012. Signaling in innate immunity and inflammation. *Cold Spring Harbor perspectives in biology*, p.a 006049.
- Osterbur, K., Mann, F.A., Kuroki, K. and DeClue, A., 2014. Multiple organ dysfunction syndrome in humans and animals. *Journal of veterinary internal medicine*, 28(4), pp.1141-1151.
- Patel, P.N., Shah, R.Y., Ferguson, J.F. and Reilly, M.P., 2015. Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases. *Arteriosclerosis, thrombosis, and vascular biology*, 35(3), pp.525-534.
- Pawar, A., Raut, A., Kalrao, V., Jacob, J., Godha, I. and Thomas, R., 2016. Etiology and clinical outcomes of neonatal and pediatric sepsis. *Archives of Pediatric Infectious Diseases*, 4(2).
- PERKENI, 2015. Konsensus Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 di Indonesia 2015. Pengurus Besar Perkumpulan Endokrinologi Indonesia, hal 11.
- Pirillo, A., Catapano, A.L. and Norata, G.D., 2015. HDL in infectious diseases and sepsis. In *High Density Lipoproteins* (pp. 483-508). Springer, Cham.
- Pirillo, A., Tibolla, G., Norata, G.D. and Catapano, A.L., 2014. HDL: to treat or not to treat. *Current atherosclerosis reports*, 16(8), p.429.
- Rader, D.J., 2006. Molecular regulation of HDL metabolism and function: implications for novel therapies. *The Journal of clinical investigation*, 116(12), pp.3090-3100.
- Ramirez, M., 2013. Multiple organ dysfunction syndrome. *Current problems in pediatric and adolescent health care*, 43(10), pp.273-277.
- Ranzani, O.T., Shankar-Hari, M., Harrison, D.A., Rabello, L.S., Salluh, J.I., Rowan, K.M. and Soares, M., 2019. A Comparison of Mortality from Sepsis in Brazil and England: The Impact of Heterogeneity in General and Sepsis-Specific Patient Characteristics. *Critical care medicine*, 47(1), pp.76-84.
- Remick, D.G., 2007. Pathophysiology of sepsis. *The American journal of pathology*, 170(5), pp.1435-1444.

- Rhee, C., Dantes, R., Epstein, L., Murphy, D.J., Seymour, C.W., Iwashyna, T.J., Kadri, S.S., Angus, D.C., Danner, R.L., Fiore, A.E. and Jernigan, J.A., 2017. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. *Jama*, 318(13), pp.1241-1249.
- Riemens, S.C., Van Tol, A., Sluiter, W.J. and Dullaart, R.P.F., 1999. Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma lecithin: cholesterol acyltransferase, phospholipid transfer protein, and cholesteryl ester transfer protein activities. *Journal of lipid research*, 40(8), pp.1459-1466.
- Schuetz, P., Castro, P. and Shapiro, N.I., 2011. Diabetes and sepsis: preclinical findings and clinical relevance. *Diabetes care*, 34(3), pp.771-778.
- Seidell, J.C., Cigolini, M., Charzewska, J., Ellsinger, B.M., Björntorp, P., Hautvast, J.G. and Szostak, W., 1991. Fat distribution and gender differences in serum lipids in men and women from four European communities. *Atherosclerosis*, 87(2-3), pp.203-210.
- Simon, V., Ho, D.D. and Karim, Q.A., 2006. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. *The Lancet*, 368(9534), pp.489-504.
- Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G.R., Chiche, J.D., Coopersmith, C.M. and Hotchkiss, R.S., 2016. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *Jama*, 315(8), pp.801-810.
- Starr, M.E. and Saito, H., 2014. Sepsis in old age: review of human and animal studies. *Aging and disease*, 5(2), p.126.
- Stoller, J., Halpin, L., Weis, M., Aplin, B., Qu, W., Georgescu, C. and Nazzal, M., 2016. Epidemiology of severe sepsis: 2008-2012. *Journal of critical care*, 31(1), pp.58-62.
- Szabo, G., Romics, J.L. and Frenzl, G., 2002. Liver in sepsis and systemic inflammatory response syndrome. *Clinics in liver disease*, 6(4), pp.1045-66.
- Taeb, A.M., Hooper, M.H. and Marik, P.E., 2017. Sepsis: current definition, pathophysiology, diagnosis, and management. *Nutrition in Clinical Practice*, 32(3), pp.296-308.
- Takeuchi, O. dan Akira, S., 2010. Pattern recognition receptors and inflammation. *Cell*, 140(6), pp.805-820.
- Tambajong, R.N., Lalenoh, D.C. and Kumaat, L., 2016. Profil penderita sepsis di ICU RSUP Prof. Dr. RD Kandou Manado periode Desember 2014–November 2015. *e-CliniC*, 4(1).
- Tanaka, S., Labreuche, J., Drumez, E., Harrois, A., Hamada, S., Vigué, B., Couret, D., Duranteau, J. and Meilhac, O., 2017. Low HDL levels in sepsis versus trauma patients in intensive care unit. *Annals of intensive care*, 7(1), p.60.
- Tanaka, S., Diallo, D., Delbosc, S., Genève, C., Zappella, N., Yong-Sang, J., Patche, J., Harrois, A., Hamada, S., Denamur, E. and Montravers, P., 2019. High-density lipoprotein (HDL) particle size and concentration changes in septic shock patients. *Annals of intensive care*, 9(1), p.68.
- Tang, B.M., Herwanto, V., McLean, A.S., 2018. Immune paralysis in Sepsis: Recent Insights and Future Development. *Annual Update in Intensive Care and Emergency Medicine 2018*, pp 13-23.
- Triantafilou, M., Mouratis, M.A., Lepper, P.M., Haston, R.M., Baldwin, F., Lowes, S., Ahmed, M.A.E., Schumann, C., Boyd, O. and Triantafilou, K., 2012. Serum proteins

- modulate lipopolysaccharide and lipoteichoic acid-induced activation and contribute to the clinical outcome of sepsis. *Virulence*, 3(2), pp.136-145.
- Tran-Dinh, A., Diallo, D., Delbosc, S., Varela-Perez, L.M., Dang, Q.B., Lapergue, B., Burillo, E., Michel, J.B., Levoye, A., Martin-Ventura, J.L. and Meilhac, O., 2013. HDL and endothelial protection. *British journal of pharmacology*, 169(3), pp.493-511.
- Trieb, M., Horvath, A., Birner-Gruenberger, R., Spindelboeck, W., Stadlbauer, V., Taschler, U., Curcic, S., Stauber, R.E., Holzer, M., Pasterk, L. and Heinemann, A., 2016. Liver disease alters high-density lipoprotein composition, metabolism and function. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*, 1861(7), pp.630-638.
- Tsunoda, F., Asztalos, I.B., Horvath, K.V., Steiner, G., Schaefer, E.J. and Asztalos, B.F., 2016. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial. *Atherosclerosis*, 247, pp.35-39.
- Van Amersfoort, E.S., Van Berkel, T.J. and Kuiper, J., 2003. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. *Clinical microbiology reviews*, 16(3), pp.379-414.
- Van Leeuwen, H.J., Heezius, E.C., Dallinga, G.M., van Strijp, J.A., Verhoef, J. and van Kessel, K.P., 2003. Lipoprotein metabolism in patients with severe sepsis. *Critical care medicine*, 31(5), pp.1359-1366.
- Vickers, K.C. and Remaley, A.T., 2014. HDL and cholesterol: life after the divorce. *Journal of lipid research*, 55(1), pp.4-12.
- Vincent JL, Moreno R, Takala J, Willatts S, De Mendon A, Bruining H, Reinhart CK, Suter PM, Thijs LG, 1996. Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. *Intensive Care Medicine*. 22(7): 707-710.
- Vitali, C., Khetarpal, S.A. and Rader, D.J., 2017. HDL cholesterol metabolism and the risk of CHD: new insights from human genetics. *Current cardiology reports*, 19(12), p.132.
- Walter, M., 2009. Interrelationships among HDL metabolism, aging, and atherosclerosis. *Arteriosclerosis, thrombosis, and vascular biology*, 29(9), pp.1244-1250.
- Wang, H. and Ma, S., 2008. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. *The American journal of emergency medicine*, 26(6), pp.711-715.
- Ward, N.S., Casserly, B. and Ayala, A., 2008. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. *Clinics in chest medicine*, 29(4), pp.617-625.
- Ware, L.B. and Matthay, M.A., 2000. The acute respiratory distress syndrome. *New England Journal of Medicine*, 342(18), pp.1334-1349.
- Weissglas-Volkov, D. and Pajukanta, P., 2010. Genetic causes of high and low serum HDL-cholesterol. *Journal of lipid research*, 51(8), pp.2032-2057.
- Wendel, M., Paul, R. and Heller, A.R., 2007. Lipoproteins in inflammation and sepsis. II. Clinical aspects. *Intensive care medicine*, 33(1), pp.25-35.

- World Health Organization, 1998. *Obesity: preventing and managing the global epidemic: report of a WHO consultation on obesity, Geneva, 3-5 June 1997* (No. WHO/NUT/NCD/98.1). Geneva: World Health Organization.
- Wood, P.J., 2012. Immunological response to infection: inflammatory and adaptive immune responses. *Anaesthesia & Intensive Care Medicine*, 13(6), pp.269-272.
- Zhu, X. and Parks, J.S., 2012. New roles of HDL in inflammation and hematopoiesis. *Annual review of nutrition*, 32, pp.161-182.